Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Export

@article{citeulike:4166069, abstract = {In a series of in vivo and in vitro experiments, the concept has been established that breast cancer cells that express LH/CG or LHRH receptors can be targeted and destroyed by constructs consisting of a lytic peptide moiety and a 15-amino acid segment of the beta-chain of CG or by an LHRH lytic peptide conjugate. Data obtained in vitro established the validity of this concept, showed the specificities of the Hecate-betaCG, and Phor14 and Phor21-betaCG conjugates in killing cells that express functional LH/CG receptors and proved that the LH/CG receptor capacity is directly related to the compound's specificity. In in vivo experiments, Hecate-betaCG, Phor14-betaCG, and Phor21-betaCG(ala) each caused highly significant reductions of tumor volume and tumor burden in nude mice bearing breast cancer xenografts; Hecate and Phor21 alone or conjugated with non-specific peptides were not effective. Most importantly, the lytic peptide conjugates were all highly effective in targeting and destroying disseminated breast cancer metastases in lymph nodes, bones, lungs and other organs.}, author = {Hansel, W. and Enright, F. and Leuschner, C.}, citeulike-article-id = {4166069}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.mce.2005.12.056}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/17101210}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=17101210}, day = {2}, doi = {10.1016/j.mce.2005.12.056}, issn = {0303-7207}, journal = {Molecular and cellular endocrinology}, keywords = {active, conjugates, hanse07apdf, hormone, membrane, peptide}, month = {January}, pages = {183--189}, posted-at = {2009-03-11 19:23:19}, priority = {2}, title = {Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.}, url = {http://dx.doi.org/10.1016/j.mce.2005.12.056}, volume = {260-262}, year = {2007} }

TY - JOUR ID - citeulike:4166069 L3 - citeulike-article-id:4166069 N2 - In a series of in vivo and in vitro experiments, the concept has been established that breast cancer cells that express LH/CG or LHRH receptors can be targeted and destroyed by constructs consisting of a lytic peptide moiety and a 15-amino acid segment of the beta-chain of CG or by an LHRH lytic peptide conjugate. Data obtained in vitro established the validity of this concept, showed the specificities of the Hecate-betaCG, and Phor14 and Phor21-betaCG conjugates in killing cells that express functional LH/CG receptors and proved that the LH/CG receptor capacity is directly related to the compound's specificity. In in vivo experiments, Hecate-betaCG, Phor14-betaCG, and Phor21-betaCG(ala) each caused highly significant reductions of tumor volume and tumor burden in nude mice bearing breast cancer xenografts; Hecate and Phor21 alone or conjugated with non-specific peptides were not effective. Most importantly, the lytic peptide conjugates were all highly effective in targeting and destroying disseminated breast cancer metastases in lymph nodes, bones, lungs and other organs. JF - Molecular and cellular endocrinology SN - 0303-7207 EP - 189 TI - Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. VL - 260-262 SP - 183 KW - active KW - conjugates KW - hanse07apdf KW - hormone KW - membrane KW - peptide AU - Hansel, W AU - Enright, F AU - Leuschner, C PY - 2007/01/02/ UR - http://dx.doi.org/10.1016/j.mce.2005.12.056 ER -